What Happened
A senior employee of KAYS’, Bryan Arnold, enrolled in a training course to obtain an Oregon psilocybin facilitator’s license that will allow him to legally oversee the cultivation of psilocybin mushrooms and related products as well as operate up to five state-licensed psilocybin administration clinics.
KAYS is moving into psychedelics therapy by adding experienced attorney Glenn E.J. Murphy to FDT’s board of directors in order to establish relations with pharmaceutical companies, develop IP and joint ventures, funding opportunities and acquisitions.
KAYS senior advisor W. David Jones said that operating a psychedelics treatment establishment “has many parallels to the cannabis industry,” adding that KAYS “is among the companies uniquely qualified to deliver the highest quality of care” to patients in need.
More On KAYS’ Business Structure
Kaya Holdings involves four majority-owned subsidiaries in both the cannabis and psychedelic industries.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
